Novo Nordisk partners with Swiss biotech firm on obesity – zebrafish to unlock new drugs

Novo Nordisk is teaming up with Swiss start-up Eracal Therapeutics, which is specialized in discovering new drugs from a zebrafish larvae platform. The firms will develop treatments targeted at food intake and other factors associated with obesity.

Zebrafish have been a hot topic withing drug discovery since the early 2000s, but it isn't until recently that the method has matured | Photo: Peter Hove Olesen/Politiken/Ritzau Scanpix

A new research collaboration between Novo Nordisk and a start-up from Switzerland, Eracal Therapeutics, has seen the light of day, a company press release announces.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs